MedTrace Logo

OM336 in Seropositive Autoimmune Diseases

NCT07229144 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-11-14

No results posted yet for this study

Summary

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.

Conditions

  • Sjogrens Disease
  • Idiopathic Inflammatory Myopathy (IIM)

Interventions

DRUG

OM336

OM336 is an engineered bispecific antibody directed against BCMA and CD3

Sponsors & Collaborators

  • Ouro Medicines

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2027-06-30
Completion
2028-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229144 on ClinicalTrials.gov